Proactive research analyst John Savin speaks to Thomas Warner after publishing a new research note on pharmaceutical group Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF).
Savin gives a preview of what readers will find in the latest note, highlighting OCT's successful completion of the initial trial phase of OCT461201 which confirmed its promising drug profile. The next step for "201" is a comprehensive multiple ascending dose study spanning 14 days, which will commence in mid-2024.
This study, critical for advancing to Phase 2 trials, will involve two distinct dosage levels and is expected to yield results by late 2024 or early 2025.
Additionally, OCT is developing a second product targeting severe facial nerve pain. This product is anticipated to enter trials in Australia, subject to funding availability.
Savin highlights that OCT's advancement to clinical trials is a crucial milestone, reflecting the company's robust position in cannabinoid research. However, both studies' initiation hinges on OCT's ability to secure funding in the first half of 2024.
Savin expresses optimism for OCT's journey ahead, with the biotech firm set to start Phase 2 studies in 2025 and explore US market opportunities.